The CEVA group is a dedicated department within IQVIA that specializes in the compilation and management of study committees. CEVA endpoint adjudication pillar supports committees that need to review additional data related to a specific event, timepoint, lab result etc. that needs to be gathered from sites or external vendors and this group primarily supports endpoint adjudication committees.
As regulatory authorities place greater importance on trial oversight for clinical events, data monitoring and more, sponsors are turning towards external oversight committees to help strengthen trial strategy and framework to better protect patient safety and scientific quality within the trial process. IQVIA Clinical Events Validation & Adjudication (CEVA) will successfully design and deliver an effective and independent oversight group management and/or endpoint adjudication strategy while simultaneously managing the projected budgets.
IQVIA Clinical Event Validation and Adjudication (CEVA) offers sponsors an umbrella of scalable, cost-efficient, end-to-end committee management and adjudication support solutions through a global team of experts who are highly experienced and ready to guide your team through the committee planning, establishment, and implementation processes.
From standalone to full-service models, IQVIA CEVA's flexible solutions allow you to build a tailored strategy that fits your trial and/or program's needs.
Related solutions
Harness the power of global human expertise combined with automation, artificial intelligence (AI) and machine learning (ML) to design, build and execute end-to-end safety solutions.
Improve the performance of your clinical trials with the power of the IQVIA CORE.
Change the model of clinical research by integrating data, expertise, analytics and technology from study design through execution to power better decisions.
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.
